
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
This new series will appear on a monthly basis and is devoted to answering perplexing questions regarding cosmetic dermatology and the use of cosmetics and skin care products.